1
|
|
2
|
Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology 2005; 215:126-48. [PMID: 16146667 DOI: 10.1016/j.tox.2005.07.018] [Citation(s) in RCA: 184] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2005] [Revised: 07/19/2005] [Accepted: 07/20/2005] [Indexed: 12/01/2022]
Abstract
Perfluorooctanesulfonate (PFOS) is a persistent acid found widely distributed in wildlife and humans. To understand the potential reproductive and developmental effects of PFOS, a two-generation reproduction study was conducted in rats. Male and female rats were dosed via oral gavage at dose levels of 0, 0.1, 0.4, 1.6, and 3.2 mg/(kg day) for 6 weeks prior to mating, during mating, and, for females, through gestation and lactation, across two generations. Due to substantial F1 neonatal toxicity observed in the 1.6 and 3.2 mg/(kg day) groups, continuation into the second generation was limited to F1 pups from the 0, 0.1, and 0.4 mg/(kg day) groups. No adverse effects were observed in F0 females or their fetuses upon caesarean sectioning at gestation day 10. Statistically significant reductions in body-weight gain and feed consumption were observed in F0 generation males and females at dose levels of 0.4 mg/(kg day) and higher, but not in F1 adults. PFOS did not affect reproductive performance (mating, estrous cycling, and fertility); however, reproductive outcome, as demonstrated by decreased length of gestation, number of implantation sites, and increased numbers of dams with stillborn pups or with all pups dying on lactation days 1-4, was affected at 3.2 mg/(kg day) in F0 dams. These effects were not observed in F1 dams at the highest dose tested, 0.4 mg/(kg day). Neonatal toxicity in F1 pups, as demonstrated by reduced survival and body-weight gain through the end of lactation, occurred at a maternal dose of 1.6 mg/(kg day) and higher while not at dose levels of 0.1 or 0.4 mg/(kg day) or in F2 pups at the 0.1 or 0.4 mg/(kg day) dose levels tested. In addition to these adverse effects, slight yet statistically significant developmental delays occurred at 0.4 (eye opening) and 1.6 mg/(kg day) (eye opening, air righting, surface righting, and pinna unfolding) in F1 pups. Based on these data, the NOAELs were as follows: reproductive function: F0> or =3.2 and F1> or =0.4 mg/(kg day); reproductive outcome: F0=1.6 and F1> or =0.4 mg/(kg day); overall parental effects: F0=0.1 and F1> or =0.4 mg/(kg day); offspring effects: F0=0.4 and F1> or =0.4 mg/(kg day). To distinguish between maternal and pup influences contributing to the perinatal mortality observed in the two-generation study, a follow-up cross-foster study was performed. Results of this study indicated that in utero exposure to PFOS causally contributed to post-natal pup mortality, and that pre-natal and post-natal exposure to PFOS was additive with respect to the toxic effects observed in pups.
Collapse
|
3
|
Abstract
This study was conducted to determine the earliest measurable response of primates to low-level perfluorooctanesulfonate (PFOS) exposure and to provide information to reduce uncertainty in human health risk assessment. Groups of male and female monkeys received 0, 0.03, 0.15, or 0.75 mg/kg/day potassium PFOS orally for 182 days. Recovery animals from each group, except the 0.03 mg/kg/day dose group, were monitored for one year after treatment. Significant adverse effects occurred only in the 0.75 mg/kg/day dose group and included compound-related mortality in 2 of 6 male monkeys, decreased body weights, increased liver weights, lowered serum total cholesterol, lowered triiodothyronine concentrations (without evidence of hypothyroidism), and lowered estradiol levels. Decreased serum total cholesterol occurred in the 0.75 mg/kg/day dose group at serum PFOS levels > 100 ppm. Hepatocellular hypertrophy and lipid vacuolation were present at term in the 0.75 mg/kg/day dose group. No peroxisomal (palmitoyl CoA oxidase) or cell proliferation (proliferating cell nuclear antigen immunohistochemistry) was detected. Complete reversal of clinical and hepatic effects and significant decreases in serum and liver PFOS occurred within 211 days posttreatment. Liver-to-serum PFOS ratios were comparable in all dose groups, with a range of 1:1 to 2:1. Serum concentrations associated with no adverse effects (0.15 mg/kg/day) were 82.6 +/- 25.2 ppm for males and 66.8 +/- 10.8 ppm for females. Comparison of serum PFOS concentrations associated with no adverse effect in this study to those reported in human blood samples (0.028 +/- 0.014 ppm) indicated an adequate margin of safety.
Collapse
|
4
|
Abstract
Developmental toxicology (teratology) studies were done on two perfluorinated compounds-perfluorooctanesulfonate (PFOS) and 2-(N-ethylperfluorooctanesulfonamido)ethyl alcohol (N-EtFOSE) in rats and rabbits. Dose selection for these oral developmental toxicity studies were based upon dose-range study results. Dose levels of 0, 1, 5, 10, and 20 mg/kg/day were used for the rat N-EtFOSE study, and dose levels of 0, 0.1, 1.0, 2.5, and 3.75 mg/kg/day were used for both the PFOS and the N-EtFOSE rabbit studies. Although no compound-related deaths occurred in the dosed pregnant females on the developmental toxicity studies, maternal toxicity (reduced body weight gain and feed consumption) was present at higher dose levels in all three studies. At high maternally toxic doses, associated effects occurred in the conceptuses--increased abortions in PFOS and N-EtFOSE rabbits, reduced fetal weights in N-EtFOSE rats and PFOS rabbits, and increased late resorptions in N-EtFOSE rabbits. Detailed external gross, soft tissue, and skeletal fetal examinations failed to reveal any compound-related malformations in either species. Similar results, that is, only effects associated with maternal toxicity, had been found in previously conducted PFOS rat developmental toxicity studies. It was concluded that these perfluorinated compounds were not selective developmental toxicants in either rats or rabbits.
Collapse
|
5
|
Abstract
Developmental toxicology (teratology) studies were done on two perfluorinated compounds—perfluorooctanesulfonate (PFOS) and 2-( N-ethylperfluorooctanesulfonamido)ethyl alcohol ( N-EtFOSE) in rats and rabbits. Dose selection for these oral developmental toxicity studies were based upon dose-range study results. Dose levels of 0,1,5,10, and 20 mg/kg/day were used for the rat N-EtFOSE study, and dose levels of 0, 0.1, 1.0, 2.5, and 3.75 mg/kg/day were used for both the PFOS and the N-EtFOSE rabbit studies. Although no compound-related deaths occurred in the dosed pregnant females on the developmental toxicity studies, maternal toxicity (reduced body weight gain and feed consumption) was present at higher dose levels in all three studies. At high maternally toxic doses, associated effects occurred in the conceptuses—increased abortions in PFOS and N-EtFOSE rabbits, reduced fetal weights in N-EtFOSE rats and PFOS rabbits, and increased late resorptions in N-EtFOSE rabbits. Detailed external gross, soft tissue, and skeletal fetal examinations failed to reveal any compound-related malformations in either species. Similar results, that is, only effects associated with maternal toxicity, had been found in previously conducted PFOS rat developmental toxicity studies. It was concluded that these perfluorinated compounds were not selective developmental toxicants in either rats or rabbits.
Collapse
|
6
|
Abstract
Atherosclerosis-induced coronary heart disease remains the major cause of death and disability in industrialized countries. Hypercholesterolemia is recognized as a causative factor in the development of atherosclerosis. While the lowering of cholesterol levels as a treatment goal has met with general agreement and acceptance, the preferred methods for doing so are still open to conjecture. This literature review discusses various factors in the hypercholesterolemia-atherosclerosis link and surveys a variety of treatment protocols including diet modification, drug therapy, surgical intervention, and plasmapheresis. Evidence is accumulating to prove that the ideal hypercholesterolemia therapy is one that reduces LDL levels while maintaining or increasing HDL levels. Because LDL-apheresis has this potential, this paper also reviews the various LDL-apheresis methods, including immunoadsorption, chemical affinity, and double-membrane filtration.
Collapse
|
7
|
Evaluation of a new microporous filtration membrane system for therapeutic plasma exchange. Vox Sang 1987; 53:89-95. [PMID: 3686940 DOI: 10.1111/j.1423-0410.1987.tb04925.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
A new therapeutic plasma exchange device developed by Sarns Inc./3M was evaluated in plasmapheresis of 20 healthy volunteers and in a multicenter clinical study of therapeutic plasma exchange that included 49 patients. Safety and efficacy of plasma separation from whole blood were assessed for a module that contains Durapore microporous surfactant-free polyvinylidene fluoride membrane (Millipore Corp., Bedford, Mass., USA). The extra-corporeal volume was 80 ml. Citrate and heparin anticoagulants were utilized. Mean plasma separation efficiency was 62% with unhindered passage of plasma proteins through the membrane pores and no hemolysis or activation of complement as measured by total hemolytic complement (CH50) and C3 conversion. Mean decrease in platelet count after procedures was 10%. No severe reactions occurred, and citrate effects (13%) were comparable to values reported with centrifugal instruments. The Sarns Inc./3M Therapore device is a rapid, safe and efficient system for plasma exchange and potentially for source plasma collection. The principal benefits are small extracorporeal volume and cell-free filtrate.
Collapse
|
8
|
Evaluation of a New Microporous Filtration Membrane System
for Therapeutic Plasma Exchange. Vox Sang 1987. [DOI: 10.1159/000461704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
9
|
Chronic oral toxicity and oncogenicity studies of flecainide, an antiarrhythmic, in rats and mice. Toxicol Appl Pharmacol 1984; 73:232-42. [PMID: 6710523 DOI: 10.1016/0041-008x(84)90328-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Chronic oral toxicity and oncogenicity studies on flecainide acetate, an antiarrhythmic compound, were made in male and female rats and mice. The duration of compound administration was 18 months in mice and 24 months in rats, and dose levels for both species were 0, 60, 30, and 15 mg/kg/day. The treated rats had dose-related significant decreases in mean body weights at all dose levels while the treated mice had a small body weight reduction (non-significant) at the higher doses. The body weight effects could not be correlated with reduced food consumption. Chronic administration of flecainide did not produce chronic toxic changes in either species. Likewise, chronic compound administration did not adversely affect survival rates; in fact, the treated groups of rats had survival rates higher than those of the controls with the differences from controls being significant for the male rat groups. All of the tumors in all groups of animals (control and treated) were considered spontaneous in nature. The incidence of the various types of tumors in the treated groups of animals was not significantly increased when compared to the control groups, with one exception. Interstitial cell adenoma in the testes was the most common tumor of the male rats and the increased survival rate of the high dose male rats had a direct effect on the incidence of this tumor. Since the high dose male rats had much better survival than the controls (90% vs 56%), a higher incidence of interstitial cell adenomas would be expected (more rats live longer, more rats with a late developing spontaneous tumor). Comparison of the incidence of interstitial cell adenomas in male rats which survived the 2-year study revealed no significant difference between controls and treated animals. Also when the incidence of interstitial cell adenomas was statistically evaluated with a life table approach, there was no indication of increased tumorigenic risk in the treated groups as compared to the controls.
Collapse
|
10
|
Ocular toxicity in beagle dogs with an experimental fluoromethane-sulfonanilide sympathomimetic agent. Drug Chem Toxicol 1980; 3:165-72. [PMID: 7227216 DOI: 10.3109/01480548009108280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
ocular lesions were detected in Beagle dogs receiving high doses of BA6650, an experimental fluoremethane-sulfonanilide sympathomimetic agent, during a preclinical safety evaluation study. The oral dose of BA6650 was increased during the 14-day study from 20 mg/kg twice daily (bid) for days 1-3 to 30 mg/kg bid for days 4-6 and finally to 40 mg/kg bid for days 7-14. Two males and two females received BA6650 while one male and one female were not dosed. Intraocular pressure in the untreated controls fluctuated during the study between 17 and 22 mmHg. Intraocular pressure decreased in 3 of 4 BA6650 treated dogs from an initial mean value of 17 to a final mean value of 8 mmHg. Ocular lesions consisting of conjunctival hyperemia, corneal opacities, epiphora, mydriasis followed by miosis, corneal herniation, hypopyon, ptosis, and anterior synechia developed in three of the animals.
Collapse
|
11
|
Effect of long term heparin administration in dogs. Drug Chem Toxicol 1978; 1:251-8. [PMID: 755671 DOI: 10.3109/01480547809105019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Because several literature reports suggested that heparin could sequester calcium from body tissues and one could reason that prolonged therapy might lead to osteoporosis, the effect of long term heparin administration was studied in dogs. Eight dogs (four males and four females) received subcutaneous injections of heparin at 250 units/kg bid, seven days a week. The female dogs were euthanatized after one year and the male dogs after two years. Pre and post-drug radiographs of the forelegs (radius, ulna, metacarpal bones) did not reveal any evidence of osteoporosis. As expected, the heparin did produce increased recalcification times and the development of occasional subcutaneous hematomas. But no effects were noted on various hematologic and blood chemistry parameters or on gross and microscopic tissue examinations.
Collapse
|
12
|
Acute mouse and chronic dog toxicity studies of danthron, dioctyl sodium sulfosuccinate, poloxalkol and combinations. Drug Chem Toxicol 1978; 1:89-101. [PMID: 90594 DOI: 10.3109/01480547709034429] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Because of an apparent typographic error in a US patent, there has been some confusion as to the acute oral toxicity of danthron and danthron in combination with dioctyl sodium sulfosuccinate (DSS). Acute oral toxicity studies in mice revealed LD50 values of greater than 7 gm/kg for danthron, 2.64 gm/kg for DSS and 3.42 gm/kg for danthron/DSS mixture (1:2 ratio). These results indicate that the lethality of these compounds is in the gm/kg range and not in the mg/kg range. A one year chronic toxicity study of danthron, dioctyl sodium sulfosuccinate, poloxalkol and combinations in dogs failed to reveal any toxic effects. In particular, there was no evidence of hepatotoxicity or of any changes in the myenteric plexuses in the chronically treated dogs.
Collapse
|
13
|
|
14
|
Reproductive, acute and subacute toxicity studies with nefopam in laboratory animals. Toxicol Appl Pharmacol 1975; 33:46-51. [PMID: 1162704 DOI: 10.1016/0041-008x(75)90242-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
15
|
Subacute and chronic toxicity studies of fluorocarbon propellants in mice, rats and dogs. Toxicol Appl Pharmacol 1973; 26:438-43. [PMID: 4767579 DOI: 10.1016/0041-008x(73)90280-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
16
|
Whole-body gamma irradiation of newborn pigs: hematologic changes. Am J Vet Res 1972; 33:1217-22. [PMID: 5022401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
17
|
Whole-body gamma irradiation of newborn pigs: pathologic changes. Am J Vet Res 1972; 33:1223-30. [PMID: 5063241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
18
|
Canine papilloma: progression of oral papilloma to carcinoma. J Natl Cancer Inst 1970; 45:915-920. [PMID: 18605417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
Squamous cell carcinoma was found in association with extensive and progressive oral papillomas in a 1 1/2-year-old male beagle. The neoplasm was in the region of the posterior portion of the right law and evidently originated from the adjacent papillomatous growths. Possible relationship between the duration and extent of papillomatosis and the appearance of malignant change, heretofore not reported, is discussed.
Collapse
|
19
|
A case of myelogenous leukemia in the cat. ZENTRALBLATT FUR VETERINARMEDIZIN. REIHE A 1970; 17:274-7. [PMID: 4996263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
20
|
Whole-body gamma irradiation of newborn pigs: the LD 50-30. Am J Vet Res 1970; 31:113-5. [PMID: 5414273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
21
|
Metastasis of a sebaceous gland carcinoma in the dog. J Am Vet Med Assoc 1969; 154:661-4. [PMID: 5812900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
22
|
Feline infectious peritonitis. J Am Vet Med Assoc 1968; 152:372-5. [PMID: 5761378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
23
|
Four cases of canine intestinal carcinoma. VETERINARY MEDICINE, SMALL ANIMAL CLINICIAN : VM, SAC 1968; 63:40-7. [PMID: 5183528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
24
|
Oncocytomas in a cat and a dog. VETERINARY MEDICINE, SMALL ANIMAL CLINICIAN : VM, SAC 1966; 61:41-3. [PMID: 5175034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|